Literature DB >> 1929458

Prognostic clinicopathologic factors in cutaneous T-cell lymphoma.

R M Martí1, T Estrach, J C Reverter, J M Mascaró.   

Abstract

Influence of clinicopathologic data on survival was analyzed in 43 patients with cutaneous T-cell lymphoma. The median age was 66 years; 35 were male and eight female. The extent of the disease, established according to a modification of the TNM system, was as follows: T1, three patients; T2, 15; T3, 14; T4, 11; N0, 15; N1, 28; M0, 38; M1, 5; B0, 37; and B1, six. The first treatment applied after staging was skin-limited therapy in seven patients and different regimens of systemic chemotherapy in 29. Seven patients received no treatment or only topical corticosteroids and tars. Median follow-up was 26 months. Nineteen patients died, with a median survival of 36.3 months. The prognostic value of age, sex, delay of diagnosis and staging, pruritus, number of sites of clinically enlarged lymph nodes, results of staging and TNM classification, erythrocyte sedimentation rate, peripheral blood cell count, liver function tests, serum lactate dehydrogenase levels, protein electrophoresis, presence of epidermotropism, thickness of cutaneous infiltrate, blastic cell percentage, mitotic index, cellular density, cutaneous eosinophilia, and follicular mucinosis was studied. Multivariate analysis (proportional hazard model with covariates) indicated that the major prognostic factors in patients with cutaneous T-cell lymphoma are as follows: (1) in a clinical model, the T category of TNM classification and the serum lactate dehydrogenase value; and (2) in a clinicopathologic model, the T category of TNM classification and the thickness of cutaneous infiltrate (measured in 10(-1) mm from the granular layer to the lower limit of the infiltrate) of the clinically thickest lesion.

Entities:  

Mesh:

Year:  1991        PMID: 1929458     DOI: 10.1001/archderm.1991.01680090075007

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  7 in total

1.  Results of radiotherapy in primary cutaneous lymphoma.

Authors:  Carlos Conill; Begoña Navalpotro; Ingrid López; Teresa Estrach
Journal:  Clin Transl Oncol       Date:  2006-06       Impact factor: 3.405

Review 2.  New targets of therapy in T-cell lymphomas.

Authors:  Jack Erter; Lapo Alinari; Kamruz Darabi; Metin Gurcan; Ramiro Garzon; Guido Marcucci; Mark A Bechtel; Henry Wong; Pierluigi Porcu
Journal:  Curr Drug Targets       Date:  2010-04       Impact factor: 3.465

3.  Advantages and implications of high dose rate (HDR) total skin electron irradiation (TSEI) for the management of Mycosis Fungoides. Indian experience.

Authors:  Dillip Kumar Parida; Goura Kishore Rath
Journal:  Rep Pract Oncol Radiother       Date:  2013-08-28

4.  Tumour-specific cytotoxic T lymphocyte activity in Th2-type Sézary syndrome: its enhancement by interferon-gamma (IFN-gamma) and IL-12 and fluctuations in association with disease activity.

Authors:  N Seo; Y Tokura; K Matsumoto; F Furukawa; M Takigawa
Journal:  Clin Exp Immunol       Date:  1998-06       Impact factor: 4.330

5.  Long-term outcomes of 1,263 patients with mycosis fungoides and Sézary syndrome from 1982 to 2009.

Authors:  Rakhshandra Talpur; Lotika Singh; Seema Daulat; Ping Liu; Sarah Seyfer; Tanya Trynosky; Wei Wei; Madeleine Duvic
Journal:  Clin Cancer Res       Date:  2012-07-31       Impact factor: 12.531

Review 6.  Safety and danger of biologic treatments in psoriasis in context of cutaneous T-cell lymphoma (CTCL).

Authors:  Karol Kołkowski; Małgorzata Sokołowska-Wojdyło
Journal:  Postepy Dermatol Alergol       Date:  2021-10-25       Impact factor: 1.837

7.  Surviving With Mycosis Fungoides for Twenty Years: An Autobiographical Case Report.

Authors:  Dillip Kumar Parida; Sandip Kumar Barik
Journal:  Cureus       Date:  2021-12-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.